Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 20, 2026 14:43 ET | Source: Teva Pharmaceutical Industries Ltd

U.S. Food and Drug Administration (FDA) Accepts Teva’s New Drug Application (NDA) for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophrenia in Adults

Olanzapine long-acting injectable (LAI) suspension (TEV-'749) has the potential to offer the efficacy of olanzapine in a once-monthly, subcutaneous formulation1If approved, TEV-'749 could help address...
February 19, 2026 07:30 ET | Source: PMGC Holdings Inc.

NorthStrive Biosciences Files 10 U.S. Patent Applications for EL-22 and EL-32 Targeting Muscle Growth and Yield Enhancement in Farmed Animals

NorthStrive Biosciences Files 10 U.S. Patent Applications for EL-22 and EL-32 Targeting Muscle Growth and Yield Enhancement in Farmed Animals
February 17, 2026 07:28 ET | Source: Nutriband Inc.

Nutriband Signs Exclusive Distribution Agreement with Innomedica for AVERSA Fentanyl and all Sports Tape products for Costa Rica

New Strategic Partnership
February 17, 2026 07:00 ET | Source: Nutriband Inc.

Nutriband Signs Exclusive Distribution Agreement with Innomedica for AVERSA Fentanyl and all Sports Tape products for Costa Rica

Distribution agreement
February 11, 2026 03:30 ET | Source: Custom Market Insights

[Latest] Global Cell Therapy Raw Materials Market Size/Share Worth USD 29.3 Billion by 2035 at a 18.9% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)

Austin, TX, USA, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Cell Therapy Raw Materials Market Size, Trends and Insights By Product (Media,...
February 06, 2026 15:54 ET | Source: Hemex Health

Hemex Health Receives FDA Breakthrough Device Designation for Gazelle® Hb Variant Test

PORTLAND, Ore., Feb. 06, 2026 (GLOBE NEWSWIRE) -- Hemex Health, a medical diagnostics company focused on decentralized testing for blood-based conditions, today announced that the U.S. Food and Drug...
February 05, 2026 09:26 ET | Source: Equity Insider

The $71 Billion Cancer Shift: Why The FDA Is Speeding Up

VANCOUVER, British Columbia, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Equity-Insider.com News Commentary – The market is waking up to a $71 billion reality[1]. We are seeing a decisive move away from broad...
February 05, 2026 09:15 ET | Source: Longeveron

Longeveron Applauds Passage of the Mikaela Naylon Give Kids a Chance Act and Reauthorization of Rare Pediatric Disease Priority Review Voucher Program

Longeveron supports the passing of the Mikaela Naylon Give Kids a Chance Act which reauthorizes the Rare Pediatric Disease Priority Review Voucher Program.
February 03, 2026 08:00 ET | Source: Byonyks

Byonyks X1: Revolutionizing Dialysis - Now FDA Cleared and Planning to start Patients in the U.S.

Byonyks’ FDA-cleared X1 advances home dialysis innovation, with Farrukh Usman leading a mission to transform patient-centric renal care globally.
January 30, 2026 10:59 ET | Source: Elevar Therapeutics

Elevar Therapeutics Announces FDA Acceptance of New Drug Application Resubmission for Rivoceranib in Combination with Camrelizumab as a First-line Systemic Treatment for Unresectable Hepatocellular Carcinoma

FORT LEE, N.J., Jan. 30, 2026 (GLOBE NEWSWIRE) -- Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd. and a fully integrated biopharmaceutical company dedicated to elevating...